Kyverna Therapeutics (KYTX) Non-Current Debt (2025 - 2026)
Kyverna Therapeutics' (KYTX) quarterly Non-Current Debt came in at $24.8 million in Q1 2026, little changed on a QoQ basis from $24.7 million in Q4 2025.
Kyverna Therapeutics (KYTX) Non-Current Debt (2025 - 2026) Analysis & Trends
Kyverna Therapeutics (KYTX) has 2 years of Non-Current Debt data on file, last reported at $24.8 million in Q1 2026.
- Quarterly Non-Current Debt changed N/A year-over-year to $24.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.8 million (changed N/A YoY) and the FY2025 annual result came in at $24.7 million, changed N/A from the prior year.
- Non-Current Debt steadied at $24.8 million in Q1 2026, from $24.7 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $24.8 million in Q1 2026 to a low of $24.7 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Kyverna Therapeutics | 505.26 Mn | 505.26 Mn | - | 24.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 24.88 Mn |
| Mar 31, 2026 | 24.81 Mn |
| Dec 31, 2025 | 24.74 Mn |